Olanzapine
Phase 3Terminated 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Bipolar Disorder
Conditions
Bipolar Disorder
Trial Timeline
Jul 1, 2002 โ Feb 1, 2006
NCT ID
NCT00194064About Olanzapine
Olanzapine is a phase 3 stage product being developed by Eli Lilly for Bipolar Disorder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00194064. Target conditions include Bipolar Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00982020 | Approved | Completed |
| NCT00618748 | Phase 3 | Completed |
| NCT00568672 | Phase 3 | Withdrawn |
| NCT00510211 | Pre-clinical | Completed |
| NCT00290121 | Approved | Completed |
| NCT00275301 | Pre-clinical | Completed |
| NCT00259272 | Phase 3 | Completed |
| NCT00113594 | Phase 3 | Completed |
| NCT00191997 | Approved | Completed |
| NCT00088036 | Phase 3 | Completed |
| NCT00100776 | Approved | Completed |
| NCT00191828 | Approved | Completed |
| NCT00194064 | Phase 3 | Terminated |
| NCT00036088 | Approved | Completed |
| NCT00260962 | Phase 2 | Completed |
| NCT00182507 | Approved | Completed |
Competing Products
20 competing products in Bipolar Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Valproate + Lithium + Risperidone + Olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Approved | 85 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E | Astellas Pharma | Phase 3 | 77 |
| FK949E + Placebo | Astellas Pharma | Phase 2/3 | 65 |
| Escitalopram + Bupropion XL | Lupin Limited | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine Hydrochloride + Lithium Carbonate | Eli Lilly | Phase 3 | 77 |
| olanzapine + lithium + valproate + carbamazepine | Eli Lilly | Phase 3 | 77 |
| Olanzapine | Eli Lilly | Approved | 85 |
| Olanzapine | Eli Lilly | Phase 3 | 77 |
| LY2979165 + Placebo | Eli Lilly | Phase 1 | 33 |
| olanzapine + divalproex sodium + placebo | Eli Lilly | Approved | 85 |
| olanzapine + risperidone | Eli Lilly | Approved | 85 |
| LY2979165 + placebo | Eli Lilly | Phase 1 | 33 |
| Topiramate + Placebo | Eli Lilly | Approved | 85 |
| olanzapine | Eli Lilly | Phase 3 | 77 |
| Olanzapine + Placebo | Eli Lilly | Phase 3 | 77 |
| Brenipatide + Placebo | Eli Lilly | Phase 2 | 52 |
| Olanzapine Fluoxetine Combination (OFC) + Placebo | Eli Lilly | Approved | 85 |